The news of Credit Suisse maintaining a Neutral rating on Cardinal Health and raising the price target from $90 to $100 indicates that the analyst sees potential for the stock price to increase. However, the Neutral rating suggests that the analyst does not expect significant outperformance or underperformance compared to the market. This may result in a neutral short-term impact on the stock price.